TriangleHEALTH PROFESSIONAL · SOURCE READING
Immune checkpoint modulation
Source: Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent SCLC / Treatment Options for Patients With Recurrent SCLC
Early phase Ib and II trials showed objective response rates of 10% to 33% with nivolumab or pembrolizumab treatment in patients with disease progression after one or more lines of chemotherapy, resulting in accelerated approval from the U.S. Food and Drug Administration. However, both agents were voluntarily withdrawn after subsequent trials failed to confirm benefit.[19,20]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice